Skip to main content
    D

    Dogwood Therapeutics, Inc. (DWTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.06
    -0.05 (-4.50%)

    Market Cap: $42.43M

    Last updated: Nov 17, 2026 at 11:01 AM ET

    Dogwood Therapeutics, Inc. (DWTX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    Dogwood Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$34.26M, operating cash flow was -$15.62M and free cash flow was -$15.62M. The quarter ended Sep 30, 2026 had revenue of $100.00K and net income of -$4.88M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $27.97M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019N/AN/AN/AN/AN/A
    Dec 2018N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2018 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Research and development$21.87M$3.53M$1.73M$8.07M$10.80M$194.01K$800.62K$854.11K
    Operating income-$27.97M-$12.23M-$5.45M-$12.32M-$15.64M-$10.01M-$2.18M-$1.96M
    Net income-$34.26M-$12.35M-$5.30M-$12.25M-$15.96M-$10.35M-$2.47M-$2.11M
    EBITDA-$27.94M-$12.19M-$5.45M-$12.25MN/A-$9.91M-$2.18M-$1.96M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$100.00K$0$0$0$0$0$0$0$0$0$0$0
    Gross profit$11.90K$0$0N/A$0$0$0-$12.18K$0$0$0N/A
    Operating income-$4.92M-$14.06M-$5.08M-$3.81M-$15.81M-$3.92M-$4.43M-$7.54M-$2.30M-$1.07M-$1.31M-$1.14M
    Net income-$4.88M-$11.53M-$4.99M-$3.78M-$15.74M-$3.81M-$10.92M-$7.73M-$2.28M-$1.05M-$1.29M-$1.10M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $56.84K by $6.47M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Total assets$90.17M$94.31M$4.17M$8.37M$15.78M$31.47M$315.90K$65.94K
    Current assets$8.43M$16.54M$4.17M$8.37M$15.78M$31.47M$315.90K$42.40K
    Cash and equivalents$6.52M$14.85M$3.32M$7.03M$14.01M$29.80M$309.38K$30.03K
    Total liabilities$15.27M$30.03M$358.55K$1.04M$1.28M$1.53M$5.26M$1.33M
    Short-term debt$56.84K$99.39KN/AN/AN/AN/AN/AN/A
    Long-term debtN/A$15.38MN/AN/AN/AN/AN/AN/A
    Shareholder equity$74.90M-$10.12M$3.81M$7.33M$14.50M$29.94M-$4.94M-$1.26M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$75.61M$80.50M$95.21M$90.17M$91.99M$96.69M$96.98M$94.31M$2.28M$3.64M$3.22M$4.17M
    Total liabilities$11.47M$12.13M$14.58M$15.27M$14.61M$14.15M$14.24M$30.03M$1.33M$500.08K$570.08K$358.55K
    Cash and equivalents$4.95M$9.61M$13.23M$6.52M$10.13M$13.40M$17.54M$14.85M$2.04M$3.02M$2.38M$3.32M
    Shareholder equity$64.13M$68.37M$80.62M$74.90M$7.26M$6.88M$7.09M$64.28M$949.43K$3.14M$2.65M$3.81M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Operating cash flow-$15.62M-$8.79M-$4.87M-$11.47M-$15.69M-$3.90M-$2.09M-$1.20M
    Capital expenditures$0$5$0$3$0$5$0$0
    Free cash flow-$15.62M-$8.79M-$4.87M-$11.47M-$15.69M-$3.90M-$2.09M-$1.20M
    Dividends paidN/AN/AN/AN/A$0$75.00KN/AN/A
    Share repurchases$53.80K$0N/A$0N/AN/AN/AN/A
    Investing cash flow$0$3.76M$0$0$0$0N/AN/A
    Financing cash flow$7.28M$16.70M$1.16M$4.49M-$97.60K$33.38M$2.37M$1.15M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$4.64M-$3.61M-$4.59M-$3.64M-$3.27M-$4.03M-$4.68M-$6.13M-$910.14K-$811.75K-$937.41K-$1.47M
    Capital expendituresN/AN/A$3$0$2$0$4$0$3$4$0$0
    Free cash flowN/AN/A-$4.59M-$3.64M-$3.27M-$4.03M-$4.68M-$6.13M-$910.14K-$811.75K-$937.41K-$1.47M
    Last 12 quarters

    Frequently Asked Questions About DWTX

    What is Dogwood Therapeutics' annual revenue?

    Dogwood Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Dogwood Therapeutics profitable?

    No. Dogwood Therapeutics reported net income of -$34.26M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does DWTX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$15.62M minus capital expenditures of $0 produced free cash flow of -$15.62M.

    How much debt does Dogwood Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $56.84K and cash and equivalents of $6.52M.